| 1340 |
National Cancer Institute |
Html |
en |
Cigar Smoking and Cancer |
A fact sheet about the health risks associated with cigar smoking. |
| U.S. cigarettes | 0.435012 |
| safe level | 0.447421 |
| daily cigar smokers | 0.575561 |
| lung disease | 0.3915 |
| U.S. Department | 0.408687 |
| Tobacco Control Research | 0.449796 |
| cigarette wrappers | 0.39436 |
| fact sheet | 0.390339 |
| smoking cigarettes | 0.411876 |
| cigar smoke | 0.9529 |
| smaller cigar | 0.493729 |
| higher level | 0.393813 |
| tobacco wrapper | 0.424842 |
| tobacco | 0.68829 |
| little cigars | 0.531809 |
| cancer-causing chemicals | 0.523406 |
| single cigar | 0.473523 |
| tobacco equivalent | 0.423502 |
| tobacco smoke | 0.637174 |
| nicotine replacement therapy | 0.395273 |
| premium cigars | 0.430441 |
| cigar tobacco | 0.599849 |
| Yes. Cigar smoke | 0.635443 |
| Cigar smoking causes | 0.545544 |
| tobacco products | 0.458198 |
|
| nonporous cigar wrapper | 0.527496 |
| longer smoking time | 0.409949 |
| cigar sizes | 0.492999 |
| Step-by-Step Quit Guide | 0.399635 |
| nicotine replacement products | 0.450092 |
| cigar smokers | 0.686977 |
| cigarettes | 0.521293 |
| help quitting smoking | 0.41788 |
| NCI fact sheet | 0.38899 |
| cigar smoking | 0.555875 |
| Cigar wrappers | 0.48618 |
| cigarette smoke | 0.705986 |
| heart disease | 0.392368 |
| large cigars | 0.512534 |
| esophageal cancer risks | 0.38664 |
| cigarette tobacco | 0.465692 |
| cigars | 0.636157 |
| cigarette smokers | 0.616772 |
| cigar smoking. Journal | 0.511307 |
| oral cavity cancers | 0.409515 |
| Services. Reducing Tobacco | 0.446373 |
| Regular cigar smokers | 0.574584 |
| oral cavity | 0.439868 |
| safe tobacco product | 0.484172 |
|
CLICK HERE |
| 1395 |
National Cancer Institute |
Html |
en |
Neuroblastoma Screening (PDQ®)–Health Professional Version |
Expert-reviewed information summary about tests used to detect or screen for neuroblastoma. |
| mass screening | 0.633479 |
| screening cohort | 0.50328 |
| final mortality rates | 0.477635 |
| neuroblastoma incidence | 0.659367 |
| standard cutoff levels | 0.372395 |
| unamplified N-myc oncogene | 0.370313 |
| Cumulative incidence | 0.42237 |
| neuroblastoma mortality | 0.605343 |
| standard deviations | 0.367415 |
| Great Britain | 0.357629 |
| positive-predictive value | 0.368634 |
| high survival rate | 0.357977 |
| performance liquid chromatography | 0.367159 |
| children | 0.418147 |
| mortality). | 0.40606 |
| mortality trends | 0.41083 |
| neuroblastoma death rate | 0.464758 |
| biologically favorable prognoses | 0.367208 |
| urinary screening | 0.478583 |
| standardized mortality ratio | 0.459583 |
| HVA cut-off level | 0.405483 |
| standard incidence ratio | 0.405002 |
| screening procedure | 0.51747 |
| once-in-a-lifetime screening test | 0.638106 |
| liquid urine samples | 0.367329 |
|
| VMA cut-off level | 0.376999 |
| mass screening program | 0.578067 |
| early-stage disease | 0.366779 |
| uncontrolled pilot experiences | 0.369023 |
| birth cohorts | 0.378521 |
| German Neuroblastoma Screening | 0.729232 |
| gas chromatography | 0.385439 |
| Japanese experience | 0.358474 |
| serial noninvasive testing | 0.364665 |
| American birth cohorts | 0.372668 |
| cumulative mortality rates | 0.516107 |
| favorable neuroblastoma | 0.427972 |
| neonatal screening | 0.550878 |
| neuroblastoma excrete | 0.450446 |
| German neuroblastoma study. | 0.461849 |
| Quebec Neuroblastoma Screening | 0.841856 |
| age-specific mortality rates | 0.512048 |
| cases | 0.401583 |
| improved survival rates | 0.372705 |
| μg/mg creatinine | 0.367455 |
| overall mortality | 0.41267 |
| 5-year birth cohort | 0.366222 |
| Neuroblastoma Screening Project | 0.944535 |
| standardized incidence ratio | 0.40319 |
|
CLICK HERE |
| 1409 |
National Cancer Institute |
Html |
en |
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Patient Version |
Expert-reviewed information summary about factors that may influence the risk of developing ovarian, fallopian tube, and primary peritoneal cancers and about research aimed at the prevention of them. |
| cancer risk factors | 0.421609 |
| oral contraceptives | 0.394634 |
| cancer treatment | 0.361951 |
| Cancer prevention | 0.515594 |
| cancer prevention trials | 0.422093 |
| invasive ovarian cancer | 0.476074 |
| primary peritoneal cancers | 0.449406 |
| nonpolyposis colorectal cancer | 0.387747 |
| cancer protective factor | 0.395471 |
| decreased risk | 0.397035 |
| prevention clinical trials | 0.392562 |
| protective factors | 0.425839 |
| gene changes | 0.362438 |
| clinical trials | 0.530283 |
| Cancer Information Service | 0.386071 |
| following PDQ summaries | 0.382587 |
| PDQ cancer information | 0.483395 |
| ovarian cancer cells | 0.47684 |
| fallopian tube | 0.63787 |
| breast/ovarian cancer syndrome | 0.3882 |
| Prevention Editorial Board | 0.384816 |
| National Cancer Institute | 0.445029 |
| primary peritoneal cancer | 0.60944 |
| increased risk | 0.383316 |
|
| cancer information summary | 0.437953 |
| PDQ Ovarian | 0.447122 |
| breast cancer prevention | 0.37908 |
| ovarian cancer | 0.978586 |
| cancer patients | 0.359808 |
| Cancer Care page | 0.379399 |
| slightly increased risk | 0.38086 |
| Early ovarian cancer | 0.493894 |
| cancer risk factor | 0.422611 |
| PDQ summary | 0.375317 |
| cancer risk assessment | 0.407064 |
| NCI PDQ cancer | 0.412389 |
| cancer clinical trials | 0.393106 |
| risk factors | 0.470948 |
| peritoneal cancer prevention | 0.426918 |
| fallopian tubes | 0.510186 |
| cancer information summaries | 0.390404 |
| hormone replacement therapy | 0.391262 |
| comprehensive cancer information | 0.390371 |
| ovarian cancer prevention | 0.478328 |
| risk | 0.594719 |
| ovarian tissue | 0.417842 |
| ovarian cancer syndrome | 0.488439 |
|
CLICK HERE |
| 1459 |
National Cancer Institute |
Html |
en |
Genetics of Endocrine and Neuroendocrine Neoplasias (PDQ®)–Health Professional Version |
Endocrine and neuroendocrine neoplasias may be inherited in syndromes such as multiple endocrine neoplasia types 1 and 2 (MEN1 and MEN2), familial pheochromocytoma and paraganglioma, and Carney-Stratakis syndrome. Learn about the genetics, clinical manifestations, and management of these hereditary cancer syndromes in this expert-reviewed summary. |
| men1 gene | 0.496062 |
| endocrine neoplasia syndrome | 0.465022 |
| moderate-risk pathogenic variants | 0.451346 |
| Zollinger-Ellison syndrome | 0.472267 |
| gene pathogenic variant | 0.461604 |
| familial multiple endocrine | 0.465896 |
| MEN1 pathogenic variant. | 0.494678 |
| M918T pathogenic variants | 0.452285 |
| Ann Surg | 0.450141 |
| Dutch MEN1 Study | 0.479758 |
| gene pathogenic variants | 0.465665 |
| pathogenic variant detection | 0.451143 |
| pathogenic variant testing | 0.449159 |
| Common pathogenic variants | 0.452259 |
| C634R pathogenic variant | 0.448895 |
| recent Dutch MEN1 | 0.461537 |
| family members | 0.473057 |
| MEN1 section | 0.451905 |
| specific pathogenic variants | 0.452497 |
| patients | 0.486964 |
| ATA-H pathogenic variants | 0.452298 |
| Preoperative multiple endocrine | 0.451658 |
| certain endocrine tumors | 0.451569 |
| Clin Endocrinol Metab | 0.506906 |
|
| MEN1 multicenter study | 0.456509 |
| pathogenic variant analysis | 0.462761 |
| et al. | 0.511423 |
| pancreaticoduodenal endocrine tumors | 0.47075 |
| MEN1 diagnosis | 0.459578 |
| MEN1 testing | 0.457802 |
| MEN1 pathogenic variants | 0.509643 |
| endocrine neoplasia type | 0.912503 |
| PUBMED Abstract | 0.487944 |
| multiple endocrine neoplasia | 0.985247 |
| pathogenic variants | 0.602394 |
| term pathogenic variant | 0.454804 |
| MEN1 Study Group | 0.48033 |
| pathogenic variant yield | 0.450166 |
| primary hyperparathyroidism | 0.470964 |
| RET pathogenic variant | 0.455734 |
| pathogenic variant prevalence | 0.453316 |
| RET pathogenic variants | 0.474875 |
| pancreatic endocrine tumors | 0.459209 |
| Abstract | 0.518889 |
| C634Y pathogenic variant | 0.449059 |
| calcitonin levels | 0.449053 |
| term multiple endocrine | 0.45844 |
| germline pathogenic variants | 0.463296 |
|
CLICK HERE |
| 1658 |
National Cancer Institute |
Html |
en |
Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood medulloblastoma, nonmedulloblastoma embryonal tumors, and pineal tumors. |
| clinical trial | 0.453805 |
| treatment | 0.609377 |
| general information | 0.246182 |
| childhood cns | 0.275323 |
| nonmedulloblastoma embryonal tumors | 0.299989 |
| cancer cells | 0.278431 |
| embryonal tumors | 0.938688 |
| brain | 0.391786 |
| chemotherapy | 0.262908 |
| CNS embryonal tumors | 0.85028 |
| clinical trial search | 0.248648 |
|
| cancer clinical trials | 0.254529 |
| brain tumors | 0.23742 |
| stem cell rescue | 0.406691 |
| children | 0.244267 |
| radiation therapy | 0.844353 |
| clinical trials | 0.725208 |
| cancer | 0.65116 |
| standard treatment | 0.256014 |
| information | 0.249598 |
| spinal cord | 0.615415 |
| CNS embryonal tumor | 0.222757 |
|
CLICK HERE |
| 1993 |
National Cancer Institute |
Html |
es |
Tratamiento del craneofaringioma infantil (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del craneofaringioma infantil |
| radiocirugÃa estereotáctica | 0.762185 |
| siguientes procedimientos | 0.374594 |
| cráneo.ampliar craneotomÃa | 0.361774 |
| siguientes especialistas | 0.367839 |
| radioterapia causa | 0.437652 |
| vÃa oral | 0.344906 |
| rayos x | 0.457932 |
| PDQ Descripción | 0.478828 |
| encéfalo benignos | 0.464072 |
| rayos gamma | 0.344103 |
| efectos tardÃos | 0.944822 |
| PDQ Efectos tardÃos | 0.500304 |
| National Cancer Institute | 0.34653 |
| tumores benignos | 0.729016 |
|
| siguientes riesgos | 0.333562 |
| Instituto Nacional | 0.381114 |
| PDQ Tratamiento | 0.757616 |
| determinados cambios | 0.335985 |
| nuevos tipos | 0.356873 |
| Physician Data Query | 0.470403 |
| sistema nervioso central | 0.413873 |
| especial llamada acelerador | 0.379394 |
| Aboutâ„¢ Brain Tumors | 0.36107 |
| simple vista | 0.352074 |
| siguientes enlaces | 0.33948 |
| pequeño recipiente | 0.345075 |
| siguientes pruebas | 0.387403 |
|
CLICK HERE |
| 2028 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer colorrectal (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre las pruebas que se usan para detectar el cáncer colorrectal. |
| accessed july | 0.61974 |
| materia fecal versus | 0.569405 |
| Cancer Statistics Review | 0.717463 |
| American Cancer Society | 0.622678 |
| prueba gfobt hemoccult-ii | 0.559469 |
| FOBT bienales | 0.553931 |
| colon distal | 0.622974 |
| Winawer SJ | 0.556908 |
| colorectal cancer | 0.922778 |
| tubo gi | 0.54546 |
| ensayo danés | 0.593036 |
| Estados Unidos | 0.603591 |
| Cancer Incidence | 0.540817 |
| IC 95Â %)Riesgo | 0.584646 |
| prueba fobt | 0.659659 |
| Sin efecto | 0.549689 |
| fecal occult blood | 0.562549 |
| detección norccap | 0.581363 |
| pruebas fobt | 0.558088 |
| SEER Cancer Statistics | 0.726137 |
| incidencia mortalidad | 0.623577 |
| cancer screening | 0.585359 |
| siguientes ciclos | 0.545695 |
| prueba gFOBT | 0.591796 |
| reino unido | 0.63003 |
|
| detección diseño | 0.605975 |
| CCR Validez | 0.68242 |
| Dukes C | 0.550116 |
| Cancer Facts | 0.543305 |
| Dukes D | 0.548677 |
| Colonoscopia Estudios | 0.59156 |
| automatizados tipo fit | 0.569845 |
| Colorectal Cancer Prevention | 0.562051 |
| Noone AM | 0.6798 |
| National Polyp Study | 0.591363 |
| PaÃses Bajos | 0.569859 |
| vÃas respiratorias | 0.55455 |
| National Cancer Institute | 0.711885 |
| Rozen P | 0.556076 |
| %)c incidencia | 0.544729 |
| Levin B | 0.551596 |
| exámenes bienales | 0.563089 |
| Sin rehidratación | 0.656137 |
| Krapcho M | 0.597589 |
| colonoscopia versus | 0.571346 |
| análisis fit | 0.820245 |
| sigmoidoscopia detecta lesiones | 0.562884 |
| Cancer Screening Trial | 0.547357 |
| adenomas distales versus | 0.573736 |
|
CLICK HERE |
| 4288 |
National Cancer Institute |
Html |
en |
Delirium and Cancer Treatment |
Delirium is a confused mental state. Symptoms may include changes in thinking and sleeping. In cancer patients, it may be caused by medicine, dehydration, or happen at the end of life. Delirium may be mistaken for depression or dementia. |
| familiar possessions | 0.460098 |
| hyperactive delirium | 0.731474 |
| questions | 0.420272 |
| family member | 0.493907 |
| health care team | 0.510247 |
| brain tumors | 0.464705 |
| poor nutrition | 0.45797 |
| judgment | 0.429189 |
| awareness | 0.413241 |
| dehydration | 0.454891 |
| health care providers | 0.496178 |
| family members | 0.628462 |
| high doses | 0.463949 |
| risk factors | 0.511453 |
| Control surroundings | 0.456835 |
| patterns | 0.413223 |
| list | 0.42027 |
| bowels | 0.414692 |
| symptoms | 0.455716 |
| hypoactive delirium | 0.762002 |
| careful observation | 0.458029 |
| Early monitoring | 0.462105 |
| decision-making | 0.411721 |
| Mixed delirium | 0.689111 |
| older age | 0.46515 |
|
| dementia | 0.412808 |
| conditions | 0.42534 |
| mental state | 0.468032 |
| different treatments | 0.463034 |
| infection | 0.411593 |
| supportive care approaches | 0.497253 |
| sedation | 0.440043 |
| life | 0.425096 |
| causes | 0.425024 |
| certain medicines | 0.522455 |
| PDQ® summary | 0.45633 |
| end | 0.425106 |
| decisions | 0.423293 |
| behavior | 0.413211 |
| delirium | 0.955275 |
| short period | 0.469724 |
| main types | 0.467622 |
| advanced cancer | 0.462991 |
| patient changes | 0.458323 |
| withdrawal | 0.412724 |
| professional version | 0.456367 |
| doctor | 0.420247 |
| bladder | 0.411574 |
| time | 0.413034 |
|
CLICK HERE |
| 17281 |
National Cancer Institute |
Html |
es |
Superar sus sentimientos |
Las personas con cáncer avanzado tienen algunos sentimientos en común. Usted verá que no está solo cuando le toque enfrentar estos sentimientos. |
|
|
CLICK HERE |
| 17283 |
National Cancer Institute |
Html |
es |
Instrucciones por adelantado |
Información sobre las instrucciones por adelantado, los cuales son documentos legales que le permiten a usted decidir con anticipación como desea que le brinden atención médica. |
| organización nacional | 0.667013 |
| aging with dignity | 0.502826 |
| resumidas cuentas | 0.476767 |
| American Bar Association | 0.490541 |
| Cinco deseos | 0.457338 |
|
| Five Wishes | 0.456319 |
| Voicing My Choices | 0.497173 |
| cuidados paliativos | 0.908507 |
| Mucha gente | 0.472554 |
|
CLICK HERE |